112 related articles for article (PubMed ID: 2920355)
1. Tamoxifen treatment increases the concentration of 52K-cathepsin D and its precursor in breast cancer tissue.
Maudelonde T; Domergue J; Henquel C; Freiss G; Brouillet JP; Simony J; Pujol H; Rochefort H
Cancer; 1989 Apr; 63(7):1265-70. PubMed ID: 2920355
[TBL] [Abstract][Full Text] [Related]
2. Structure, function, regulation and clinical significance of the 52K pro-cathepsin D secreted by breast cancer cells.
Rochefort H; Augereau P; Briozzo P; Capony F; Cavailles V; Freiss G; Garcia M; Maudelonde T; Morisset M; Vignon F
Biochimie; 1988 Jul; 70(7):943-9. PubMed ID: 3145027
[TBL] [Abstract][Full Text] [Related]
3. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters.
Maudelonde T; Khalaf S; Garcia M; Freiss G; Duporte J; Benatia M; Rogier H; Paolucci F; Simony J; Pujol H
Cancer Res; 1988 Jan; 48(2):462-6. PubMed ID: 3275497
[TBL] [Abstract][Full Text] [Related]
4. In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.
Maudelonde T; Escot C; Pujol P; Rouanet P; Defrenne A; Brouillet JP; Rochefort H
Eur J Cancer; 1994; 30A(14):2049-53. PubMed ID: 7857701
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin D in breast cancer.
Rochefort H
Breast Cancer Res Treat; 1990 Jul; 16(1):3-13. PubMed ID: 2207345
[TBL] [Abstract][Full Text] [Related]
6. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
[TBL] [Abstract][Full Text] [Related]
7. The estrogen-regulated 52K-cathepsin-D in breast cancer: from biology to clinical applications.
Rochefort H; Capony F; Augereau P; Cavailles V; Garcia M; Morisset M; Freiss G; Maudelonde T; Vignon F
Int J Rad Appl Instrum B; 1987; 14(4):377-84. PubMed ID: 3654255
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin D: a protease involved in breast cancer metastasis.
Rochefort H; Capony F; Garcia M
Cancer Metastasis Rev; 1990 Dec; 9(4):321-31. PubMed ID: 1965795
[TBL] [Abstract][Full Text] [Related]
9. A hormone-regulated pro-cathepsin D secreted by human mammary cancer cells.
Capony F; Garcia M; Montcourrier P; Cavailles V; Augereau P; Briozzo P; Vignon F; Rochefort H
Biochem Soc Trans; 1989 Feb; 17(1):31-3. PubMed ID: 2714515
[No Abstract] [Full Text] [Related]
10. Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.
Cavailles V; Augereau P; Garcia M; Rochefort H
Nucleic Acids Res; 1988 Mar; 16(5):1903-19. PubMed ID: 3282224
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study.
Henry JA; McCarthy AL; Angus B; Westley BR; May FE; Nicholson S; Cairns J; Harris AL; Horne CH
Cancer; 1990 Jan; 65(2):265-71. PubMed ID: 2295049
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer.
Rochefort H; Cavailles V; Augereau P; Capony F; Maudelonde T; Touitou I; Garcia M
J Steroid Biochem; 1989; 34(1-6):177-82. PubMed ID: 2626016
[TBL] [Abstract][Full Text] [Related]
13. Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11.
Augereau P; Garcia M; Mattei MG; Cavailles V; Depadova F; Derocq D; Capony F; Ferrara P; Rochefort H
Mol Endocrinol; 1988 Feb; 2(2):186-92. PubMed ID: 3398849
[TBL] [Abstract][Full Text] [Related]
14. Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D.
Brouillet JP; Spyratos F; Hacene K; Fauque J; Freiss G; Dupont F; Maudelonde T; Rochefort H
Eur J Cancer; 1993; 29A(9):1248-51. PubMed ID: 8343262
[TBL] [Abstract][Full Text] [Related]
15. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen.
Dittadi R; Biganzoli E; Boracchi P; Salbe C; Mione R; Gatti C; Gion M
Int J Biol Markers; 1998; 13(1):30-41. PubMed ID: 9681297
[TBL] [Abstract][Full Text] [Related]
16. Regulation, clinical and biological significance of cathepsin D in breast cancer.
García M; Augereau P; Briozzo P; Capony F; Cavailles V; Freiss G; Maudelonde T; Montcourrier P; Vignon F; Rochefort H
Rev Esp Fisiol; 1990 Mar; 46(1):39-41. PubMed ID: 2204091
[TBL] [Abstract][Full Text] [Related]
17. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells.
Capony F; Rougeot C; Montcourrier P; Cavailles V; Salazar G; Rochefort H
Cancer Res; 1989 Jul; 49(14):3904-9. PubMed ID: 2736531
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis?
Rochefort H; Capony F; Garcia M; Cavaillès V; Freiss G; Chambon M; Morisset M; Vignon F
J Cell Biochem; 1987 Sep; 35(1):17-29. PubMed ID: 3312245
[TBL] [Abstract][Full Text] [Related]
19. Characterization and properties of two monoclonal antibodies specific for the Mr 52,000 precursor of cathepsin D in human breast cancer cells.
Freiss G; Vignon F; Rochefort H
Cancer Res; 1988 Jul; 48(13):3709-15. PubMed ID: 2454153
[TBL] [Abstract][Full Text] [Related]
20. Decreased secretion of Cathepsin D in breast cancer in vivo by tamoxifen: mediated by the mannose-6-phosphate/IGF-II receptor?
Dabrosin C; Johansson AC; Ollinger K
Breast Cancer Res Treat; 2004 Jun; 85(3):229-38. PubMed ID: 15111761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
